[1]王支琼,王晓川,曹萍,等.带状疱疹后遗神经痛154例危险因素分析[J].中国皮肤性病学杂志,2014,28(11):1189.
[2]WADIH A, REHM PK, DENG C, et al. Active herpes zoster infection with cutaneous manifestation and adenopathy on FDG PET/CT[J]. Radiol Case Rep,2015 ,10(3) :27-29.
[3]伍小敏,于泳健,蔡放,王宏法.带状疱疹后遗神经痛的发病相关因素分析[J].中华全科医学,2016,14(3):352-354.
[4]洁,吴跃申,水润英,等.老年带状疱疹后遗神经痛的危险因素研究[J].老年医学与保健,2016,22(1):48-51.
[5]JEON YH. Herpes Zoster and Postherpetic Neuralgia :Practical Consid eration for Prevention and Treatment [J].Korean J Pain, 2015,28 (3) :177-84.
[6]徐灵凤,卓高豹,徐晓静.腰椎间盘突出症患者行经皮脊柱内镜下椎间盘摘除术后康复路径管理措施的统计分析[J].中国医院统计,2018,25(3):221-224.
[7]TAKAO Y, MIYAZAKI Y, OKEDA M, et al. Incidences of Herpes Zoster and Postherpetic Neuralgia in Japanese Adults Aged 50 Years and Older From a Communitybased Prospective Cohort Study:The SHEZ Study[J].J Epidemiol,2015,25(10) :617-25.
[8]RICE A SC,DWORKIN RH,MC CARTHY TD,et al.EMA401,an orally administered highly selective angiotensin II type2 receptor antagonist,as a novel treatment for postherpetic neuralgia:a randomised,doubleblind,placebocontrolled phase 2 clinical trial[J].The Lancet,2014,383(9929):1637-1647.
[9]丁杨,陶小华.氦氖激光联合普瑞巴林治疗带状疱疹后遗神经痛的临床疗效观察[J].健康研究,2017,37(5):560-561.
[10]徐武生,于建斌,罗杨,等.50岁以上带状疱疹患者后遗神经痛的影响因素及其防治[J].中国皮肤性病学杂志,2014,28(12):1260-1261.[11]卢忠明,程浩.带状疱疹后遗神经痛高危因素分析及其预报模型的建立[J].临床皮肤科杂志,2015,44(4):207-209.
[12]JOHNSON RW,RICE AS.Clinical practice:Postherpetic neuralgia[J].N Engl J Med,2014,371(16):1526-1533.
[13]李彤彤,王雅莉,赵艳霞.带状疱疹后神经痛的危险因素及防治的研究进展[J].中国中西医结合皮肤性病学杂志,2017,16(3):279-282.
[14]覃万翔,石英,崔剑,等.带状疱疹后遗神经痛患者用药依从性及影响因素的横断面调查研究[J].重庆医学,2018,47(8):1084-1086.
[15]赵久敏,王琳琳,韦华,等.带状疱疹后遗神经痛危险因素的Logistic分析[J].现代预防医学,2015,42(7):1183-1184. |